Armata Pharmaceuticals receives two U.S. patents for phage therapies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. RTX
6. COF
7. SMCI
8. GOOGL
9. TSLA
10. CRWV

Go back to Armata Pharmaceuticals receives two U.S. patents for phage therapies

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

October 7, 2026 7:00 AM EDT

Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02, until at least 2041

LOS ANGELES, Oct. 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced issuance... More